08-19-2019, 10:41 AM
Not a big fan of ABBV, though I haven't looked at it closely. Losing Humira patent is going to hurt, no matter what. I'm not too sure about this AGN acquisition either as they seem to have their own issues too. There are pharma plays out there with less risk.
Again, keeping up with the thread:
Bought LHX at the open.
Again, keeping up with the thread:
Bought LHX at the open.